Review



lif neutralizing antibody  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    R&D Systems lif neutralizing antibody
    ( A ) Heatmap of cell viability after 5 days’ treatment with 1 μmol/L of each single agent (rows) per various lung cancer cell lines (columns) relative to DMSO control. Commercially available agents used are in . ( B ) Bar graph of IC 50 values of various indicated lung cancer cell lines in response to trametinib. IC 50 of NE and non-NE tSCLC cell lines is shown in red and blue, respectively. ( C ) Dose-response curve of trametinib in tSCLC cell lines (blue: NE, red: non-NE). Cell viability was assessed by CTG after 120 hours ( n = 6, technical replicate, mean ± SD). ( D ) NE tSCLC cell viability was assayed by CTG following treatment with indicated concentration of <t>LIF</t> and IL-6 for 5 days. ( E ) qPCR analysis of LIF mRNA expression levels in non-NE tSCLC cell lines treated with 10 nmol/L trametinib 2 and 6 hours. Gene expression was normalized to GUSB and shown as relative to that of DMSO-treated control ( n = 3, technical replicate, mean ± SD). ****= P ≤ 0.001 by 2-way ANOVA with Šídák’s multiple comparisons test. ( F ) Various cell lines were analyzed for LIF expression by ELISA. Data are presented as mean ± SD ( n = 3. Technical replicates). ( G ) GFP-expressing DFCI112F and DFCI190F cells were incubated with CM from their corresponding adherent cell line pairs pretreated with either LIF <t>neutralizing</t> antibody (500 ng/mL) or control IgG and monitored in real time via IncuCyte imager for green fluorescence intensity. ( H and I ) GFP expressing DFCI112F ( H ) and DFCI190 ( I ) cells were incubated with CM from their adherent cell line pairs pretreated with siRNA against LIF or unrelated sequence and monitored via IncuCyte imager. LIF knockdown efficiency was tested using ELISA ( n = 3, technical replicate, mean ± SD). ( J ) The schema illustrating the interaction between NE and non-NE tSCLC cells through LIF.
    Lif Neutralizing Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 43 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lif neutralizing antibody/product/R&D Systems
    Average 93 stars, based on 43 article reviews
    lif neutralizing antibody - by Bioz Stars, 2026-05
    93/100 stars

    Images

    1) Product Images from "EGFR -mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy"

    Article Title: EGFR -mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy

    Journal: JCI Insight

    doi: 10.1172/jci.insight.197008

    ( A ) Heatmap of cell viability after 5 days’ treatment with 1 μmol/L of each single agent (rows) per various lung cancer cell lines (columns) relative to DMSO control. Commercially available agents used are in . ( B ) Bar graph of IC 50 values of various indicated lung cancer cell lines in response to trametinib. IC 50 of NE and non-NE tSCLC cell lines is shown in red and blue, respectively. ( C ) Dose-response curve of trametinib in tSCLC cell lines (blue: NE, red: non-NE). Cell viability was assessed by CTG after 120 hours ( n = 6, technical replicate, mean ± SD). ( D ) NE tSCLC cell viability was assayed by CTG following treatment with indicated concentration of LIF and IL-6 for 5 days. ( E ) qPCR analysis of LIF mRNA expression levels in non-NE tSCLC cell lines treated with 10 nmol/L trametinib 2 and 6 hours. Gene expression was normalized to GUSB and shown as relative to that of DMSO-treated control ( n = 3, technical replicate, mean ± SD). ****= P ≤ 0.001 by 2-way ANOVA with Šídák’s multiple comparisons test. ( F ) Various cell lines were analyzed for LIF expression by ELISA. Data are presented as mean ± SD ( n = 3. Technical replicates). ( G ) GFP-expressing DFCI112F and DFCI190F cells were incubated with CM from their corresponding adherent cell line pairs pretreated with either LIF neutralizing antibody (500 ng/mL) or control IgG and monitored in real time via IncuCyte imager for green fluorescence intensity. ( H and I ) GFP expressing DFCI112F ( H ) and DFCI190 ( I ) cells were incubated with CM from their adherent cell line pairs pretreated with siRNA against LIF or unrelated sequence and monitored via IncuCyte imager. LIF knockdown efficiency was tested using ELISA ( n = 3, technical replicate, mean ± SD). ( J ) The schema illustrating the interaction between NE and non-NE tSCLC cells through LIF.
    Figure Legend Snippet: ( A ) Heatmap of cell viability after 5 days’ treatment with 1 μmol/L of each single agent (rows) per various lung cancer cell lines (columns) relative to DMSO control. Commercially available agents used are in . ( B ) Bar graph of IC 50 values of various indicated lung cancer cell lines in response to trametinib. IC 50 of NE and non-NE tSCLC cell lines is shown in red and blue, respectively. ( C ) Dose-response curve of trametinib in tSCLC cell lines (blue: NE, red: non-NE). Cell viability was assessed by CTG after 120 hours ( n = 6, technical replicate, mean ± SD). ( D ) NE tSCLC cell viability was assayed by CTG following treatment with indicated concentration of LIF and IL-6 for 5 days. ( E ) qPCR analysis of LIF mRNA expression levels in non-NE tSCLC cell lines treated with 10 nmol/L trametinib 2 and 6 hours. Gene expression was normalized to GUSB and shown as relative to that of DMSO-treated control ( n = 3, technical replicate, mean ± SD). ****= P ≤ 0.001 by 2-way ANOVA with Šídák’s multiple comparisons test. ( F ) Various cell lines were analyzed for LIF expression by ELISA. Data are presented as mean ± SD ( n = 3. Technical replicates). ( G ) GFP-expressing DFCI112F and DFCI190F cells were incubated with CM from their corresponding adherent cell line pairs pretreated with either LIF neutralizing antibody (500 ng/mL) or control IgG and monitored in real time via IncuCyte imager for green fluorescence intensity. ( H and I ) GFP expressing DFCI112F ( H ) and DFCI190 ( I ) cells were incubated with CM from their adherent cell line pairs pretreated with siRNA against LIF or unrelated sequence and monitored via IncuCyte imager. LIF knockdown efficiency was tested using ELISA ( n = 3, technical replicate, mean ± SD). ( J ) The schema illustrating the interaction between NE and non-NE tSCLC cells through LIF.

    Techniques Used: Control, Concentration Assay, Expressing, Gene Expression, Enzyme-linked Immunosorbent Assay, Incubation, Fluorescence, Sequencing, Knockdown



    Similar Products

    lif  (Miltenyi Biotec)
    94
    Miltenyi Biotec lif
    Lif, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lif/product/Miltenyi Biotec
    Average 94 stars, based on 1 article reviews
    lif - by Bioz Stars, 2026-05
    94/100 stars
    		  Buy from Supplier
    lif neutralizing antibody  (R&D Systems)
    93
    R&D Systems lif neutralizing antibody
    ( A ) Heatmap of cell viability after 5 days’ treatment with 1 μmol/L of each single agent (rows) per various lung cancer cell lines (columns) relative to DMSO control. Commercially available agents used are in . ( B ) Bar graph of IC 50 values of various indicated lung cancer cell lines in response to trametinib. IC 50 of NE and non-NE tSCLC cell lines is shown in red and blue, respectively. ( C ) Dose-response curve of trametinib in tSCLC cell lines (blue: NE, red: non-NE). Cell viability was assessed by CTG after 120 hours ( n = 6, technical replicate, mean ± SD). ( D ) NE tSCLC cell viability was assayed by CTG following treatment with indicated concentration of <t>LIF</t> and IL-6 for 5 days. ( E ) qPCR analysis of LIF mRNA expression levels in non-NE tSCLC cell lines treated with 10 nmol/L trametinib 2 and 6 hours. Gene expression was normalized to GUSB and shown as relative to that of DMSO-treated control ( n = 3, technical replicate, mean ± SD). ****= P ≤ 0.001 by 2-way ANOVA with Šídák’s multiple comparisons test. ( F ) Various cell lines were analyzed for LIF expression by ELISA. Data are presented as mean ± SD ( n = 3. Technical replicates). ( G ) GFP-expressing DFCI112F and DFCI190F cells were incubated with CM from their corresponding adherent cell line pairs pretreated with either LIF <t>neutralizing</t> antibody (500 ng/mL) or control IgG and monitored in real time via IncuCyte imager for green fluorescence intensity. ( H and I ) GFP expressing DFCI112F ( H ) and DFCI190 ( I ) cells were incubated with CM from their adherent cell line pairs pretreated with siRNA against LIF or unrelated sequence and monitored via IncuCyte imager. LIF knockdown efficiency was tested using ELISA ( n = 3, technical replicate, mean ± SD). ( J ) The schema illustrating the interaction between NE and non-NE tSCLC cells through LIF.
    Lif Neutralizing Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/lif neutralizing antibody/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    lif neutralizing antibody - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    anti human lif  (R&D Systems)
    93
    R&D Systems anti human lif
    ( A ) Heatmap of cell viability after 5 days’ treatment with 1 μmol/L of each single agent (rows) per various lung cancer cell lines (columns) relative to DMSO control. Commercially available agents used are in . ( B ) Bar graph of IC 50 values of various indicated lung cancer cell lines in response to trametinib. IC 50 of NE and non-NE tSCLC cell lines is shown in red and blue, respectively. ( C ) Dose-response curve of trametinib in tSCLC cell lines (blue: NE, red: non-NE). Cell viability was assessed by CTG after 120 hours ( n = 6, technical replicate, mean ± SD). ( D ) NE tSCLC cell viability was assayed by CTG following treatment with indicated concentration of <t>LIF</t> and IL-6 for 5 days. ( E ) qPCR analysis of LIF mRNA expression levels in non-NE tSCLC cell lines treated with 10 nmol/L trametinib 2 and 6 hours. Gene expression was normalized to GUSB and shown as relative to that of DMSO-treated control ( n = 3, technical replicate, mean ± SD). ****= P ≤ 0.001 by 2-way ANOVA with Šídák’s multiple comparisons test. ( F ) Various cell lines were analyzed for LIF expression by ELISA. Data are presented as mean ± SD ( n = 3. Technical replicates). ( G ) GFP-expressing DFCI112F and DFCI190F cells were incubated with CM from their corresponding adherent cell line pairs pretreated with either LIF <t>neutralizing</t> antibody (500 ng/mL) or control IgG and monitored in real time via IncuCyte imager for green fluorescence intensity. ( H and I ) GFP expressing DFCI112F ( H ) and DFCI190 ( I ) cells were incubated with CM from their adherent cell line pairs pretreated with siRNA against LIF or unrelated sequence and monitored via IncuCyte imager. LIF knockdown efficiency was tested using ELISA ( n = 3, technical replicate, mean ± SD). ( J ) The schema illustrating the interaction between NE and non-NE tSCLC cells through LIF.
    Anti Human Lif, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti human lif/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    anti human lif - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    rabbit anti human anti lif antibody  (Atlas Antibodies)
    93
    Atlas Antibodies rabbit anti human anti lif antibody
    ( A ) Heatmap of cell viability after 5 days’ treatment with 1 μmol/L of each single agent (rows) per various lung cancer cell lines (columns) relative to DMSO control. Commercially available agents used are in . ( B ) Bar graph of IC 50 values of various indicated lung cancer cell lines in response to trametinib. IC 50 of NE and non-NE tSCLC cell lines is shown in red and blue, respectively. ( C ) Dose-response curve of trametinib in tSCLC cell lines (blue: NE, red: non-NE). Cell viability was assessed by CTG after 120 hours ( n = 6, technical replicate, mean ± SD). ( D ) NE tSCLC cell viability was assayed by CTG following treatment with indicated concentration of <t>LIF</t> and IL-6 for 5 days. ( E ) qPCR analysis of LIF mRNA expression levels in non-NE tSCLC cell lines treated with 10 nmol/L trametinib 2 and 6 hours. Gene expression was normalized to GUSB and shown as relative to that of DMSO-treated control ( n = 3, technical replicate, mean ± SD). ****= P ≤ 0.001 by 2-way ANOVA with Šídák’s multiple comparisons test. ( F ) Various cell lines were analyzed for LIF expression by ELISA. Data are presented as mean ± SD ( n = 3. Technical replicates). ( G ) GFP-expressing DFCI112F and DFCI190F cells were incubated with CM from their corresponding adherent cell line pairs pretreated with either LIF <t>neutralizing</t> antibody (500 ng/mL) or control IgG and monitored in real time via IncuCyte imager for green fluorescence intensity. ( H and I ) GFP expressing DFCI112F ( H ) and DFCI190 ( I ) cells were incubated with CM from their adherent cell line pairs pretreated with siRNA against LIF or unrelated sequence and monitored via IncuCyte imager. LIF knockdown efficiency was tested using ELISA ( n = 3, technical replicate, mean ± SD). ( J ) The schema illustrating the interaction between NE and non-NE tSCLC cells through LIF.
    Rabbit Anti Human Anti Lif Antibody, supplied by Atlas Antibodies, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/rabbit anti human anti lif antibody/product/Atlas Antibodies
    Average 93 stars, based on 1 article reviews
    rabbit anti human anti lif antibody - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    anti human leukemia inhibitory factor lif antibodies  (R&D Systems)
    93
    R&D Systems anti human leukemia inhibitory factor lif antibodies
    ( A ) Heatmap of cell viability after 5 days’ treatment with 1 μmol/L of each single agent (rows) per various lung cancer cell lines (columns) relative to DMSO control. Commercially available agents used are in . ( B ) Bar graph of IC 50 values of various indicated lung cancer cell lines in response to trametinib. IC 50 of NE and non-NE tSCLC cell lines is shown in red and blue, respectively. ( C ) Dose-response curve of trametinib in tSCLC cell lines (blue: NE, red: non-NE). Cell viability was assessed by CTG after 120 hours ( n = 6, technical replicate, mean ± SD). ( D ) NE tSCLC cell viability was assayed by CTG following treatment with indicated concentration of <t>LIF</t> and IL-6 for 5 days. ( E ) qPCR analysis of LIF mRNA expression levels in non-NE tSCLC cell lines treated with 10 nmol/L trametinib 2 and 6 hours. Gene expression was normalized to GUSB and shown as relative to that of DMSO-treated control ( n = 3, technical replicate, mean ± SD). ****= P ≤ 0.001 by 2-way ANOVA with Šídák’s multiple comparisons test. ( F ) Various cell lines were analyzed for LIF expression by ELISA. Data are presented as mean ± SD ( n = 3. Technical replicates). ( G ) GFP-expressing DFCI112F and DFCI190F cells were incubated with CM from their corresponding adherent cell line pairs pretreated with either LIF <t>neutralizing</t> antibody (500 ng/mL) or control IgG and monitored in real time via IncuCyte imager for green fluorescence intensity. ( H and I ) GFP expressing DFCI112F ( H ) and DFCI190 ( I ) cells were incubated with CM from their adherent cell line pairs pretreated with siRNA against LIF or unrelated sequence and monitored via IncuCyte imager. LIF knockdown efficiency was tested using ELISA ( n = 3, technical replicate, mean ± SD). ( J ) The schema illustrating the interaction between NE and non-NE tSCLC cells through LIF.
    Anti Human Leukemia Inhibitory Factor Lif Antibodies, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti human leukemia inhibitory factor lif antibodies/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    anti human leukemia inhibitory factor lif antibodies - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    anti lif  (R&D Systems)
    93
    R&D Systems anti lif
    ( A ) Heatmap of cell viability after 5 days’ treatment with 1 μmol/L of each single agent (rows) per various lung cancer cell lines (columns) relative to DMSO control. Commercially available agents used are in . ( B ) Bar graph of IC 50 values of various indicated lung cancer cell lines in response to trametinib. IC 50 of NE and non-NE tSCLC cell lines is shown in red and blue, respectively. ( C ) Dose-response curve of trametinib in tSCLC cell lines (blue: NE, red: non-NE). Cell viability was assessed by CTG after 120 hours ( n = 6, technical replicate, mean ± SD). ( D ) NE tSCLC cell viability was assayed by CTG following treatment with indicated concentration of <t>LIF</t> and IL-6 for 5 days. ( E ) qPCR analysis of LIF mRNA expression levels in non-NE tSCLC cell lines treated with 10 nmol/L trametinib 2 and 6 hours. Gene expression was normalized to GUSB and shown as relative to that of DMSO-treated control ( n = 3, technical replicate, mean ± SD). ****= P ≤ 0.001 by 2-way ANOVA with Šídák’s multiple comparisons test. ( F ) Various cell lines were analyzed for LIF expression by ELISA. Data are presented as mean ± SD ( n = 3. Technical replicates). ( G ) GFP-expressing DFCI112F and DFCI190F cells were incubated with CM from their corresponding adherent cell line pairs pretreated with either LIF <t>neutralizing</t> antibody (500 ng/mL) or control IgG and monitored in real time via IncuCyte imager for green fluorescence intensity. ( H and I ) GFP expressing DFCI112F ( H ) and DFCI190 ( I ) cells were incubated with CM from their adherent cell line pairs pretreated with siRNA against LIF or unrelated sequence and monitored via IncuCyte imager. LIF knockdown efficiency was tested using ELISA ( n = 3, technical replicate, mean ± SD). ( J ) The schema illustrating the interaction between NE and non-NE tSCLC cells through LIF.
    Anti Lif, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti lif/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    anti lif - by Bioz Stars, 2026-05
    93/100 stars
    		  Buy from Supplier
    humanized anti-lif antibody msc-1  (AstraZeneca ltd)
    90
    AstraZeneca ltd humanized anti-lif antibody msc-1
    ( A ) Heatmap of cell viability after 5 days’ treatment with 1 μmol/L of each single agent (rows) per various lung cancer cell lines (columns) relative to DMSO control. Commercially available agents used are in . ( B ) Bar graph of IC 50 values of various indicated lung cancer cell lines in response to trametinib. IC 50 of NE and non-NE tSCLC cell lines is shown in red and blue, respectively. ( C ) Dose-response curve of trametinib in tSCLC cell lines (blue: NE, red: non-NE). Cell viability was assessed by CTG after 120 hours ( n = 6, technical replicate, mean ± SD). ( D ) NE tSCLC cell viability was assayed by CTG following treatment with indicated concentration of <t>LIF</t> and IL-6 for 5 days. ( E ) qPCR analysis of LIF mRNA expression levels in non-NE tSCLC cell lines treated with 10 nmol/L trametinib 2 and 6 hours. Gene expression was normalized to GUSB and shown as relative to that of DMSO-treated control ( n = 3, technical replicate, mean ± SD). ****= P ≤ 0.001 by 2-way ANOVA with Šídák’s multiple comparisons test. ( F ) Various cell lines were analyzed for LIF expression by ELISA. Data are presented as mean ± SD ( n = 3. Technical replicates). ( G ) GFP-expressing DFCI112F and DFCI190F cells were incubated with CM from their corresponding adherent cell line pairs pretreated with either LIF <t>neutralizing</t> antibody (500 ng/mL) or control IgG and monitored in real time via IncuCyte imager for green fluorescence intensity. ( H and I ) GFP expressing DFCI112F ( H ) and DFCI190 ( I ) cells were incubated with CM from their adherent cell line pairs pretreated with siRNA against LIF or unrelated sequence and monitored via IncuCyte imager. LIF knockdown efficiency was tested using ELISA ( n = 3, technical replicate, mean ± SD). ( J ) The schema illustrating the interaction between NE and non-NE tSCLC cells through LIF.
    Humanized Anti Lif Antibody Msc 1, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/humanized anti-lif antibody msc-1/product/AstraZeneca ltd
    Average 90 stars, based on 1 article reviews
    humanized anti-lif antibody msc-1 - by Bioz Stars, 2026-05
    90/100 stars
    		  Buy from Supplier
    human lif detector antibody  (Danaher Inc)
    86
    Danaher Inc human lif detector antibody
    ( A ) Heatmap of cell viability after 5 days’ treatment with 1 μmol/L of each single agent (rows) per various lung cancer cell lines (columns) relative to DMSO control. Commercially available agents used are in . ( B ) Bar graph of IC 50 values of various indicated lung cancer cell lines in response to trametinib. IC 50 of NE and non-NE tSCLC cell lines is shown in red and blue, respectively. ( C ) Dose-response curve of trametinib in tSCLC cell lines (blue: NE, red: non-NE). Cell viability was assessed by CTG after 120 hours ( n = 6, technical replicate, mean ± SD). ( D ) NE tSCLC cell viability was assayed by CTG following treatment with indicated concentration of <t>LIF</t> and IL-6 for 5 days. ( E ) qPCR analysis of LIF mRNA expression levels in non-NE tSCLC cell lines treated with 10 nmol/L trametinib 2 and 6 hours. Gene expression was normalized to GUSB and shown as relative to that of DMSO-treated control ( n = 3, technical replicate, mean ± SD). ****= P ≤ 0.001 by 2-way ANOVA with Šídák’s multiple comparisons test. ( F ) Various cell lines were analyzed for LIF expression by ELISA. Data are presented as mean ± SD ( n = 3. Technical replicates). ( G ) GFP-expressing DFCI112F and DFCI190F cells were incubated with CM from their corresponding adherent cell line pairs pretreated with either LIF <t>neutralizing</t> antibody (500 ng/mL) or control IgG and monitored in real time via IncuCyte imager for green fluorescence intensity. ( H and I ) GFP expressing DFCI112F ( H ) and DFCI190 ( I ) cells were incubated with CM from their adherent cell line pairs pretreated with siRNA against LIF or unrelated sequence and monitored via IncuCyte imager. LIF knockdown efficiency was tested using ELISA ( n = 3, technical replicate, mean ± SD). ( J ) The schema illustrating the interaction between NE and non-NE tSCLC cells through LIF.
    Human Lif Detector Antibody, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human lif detector antibody/product/Danaher Inc
    Average 86 stars, based on 1 article reviews
    human lif detector antibody - by Bioz Stars, 2026-05
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A ) Heatmap of cell viability after 5 days’ treatment with 1 μmol/L of each single agent (rows) per various lung cancer cell lines (columns) relative to DMSO control. Commercially available agents used are in . ( B ) Bar graph of IC 50 values of various indicated lung cancer cell lines in response to trametinib. IC 50 of NE and non-NE tSCLC cell lines is shown in red and blue, respectively. ( C ) Dose-response curve of trametinib in tSCLC cell lines (blue: NE, red: non-NE). Cell viability was assessed by CTG after 120 hours ( n = 6, technical replicate, mean ± SD). ( D ) NE tSCLC cell viability was assayed by CTG following treatment with indicated concentration of LIF and IL-6 for 5 days. ( E ) qPCR analysis of LIF mRNA expression levels in non-NE tSCLC cell lines treated with 10 nmol/L trametinib 2 and 6 hours. Gene expression was normalized to GUSB and shown as relative to that of DMSO-treated control ( n = 3, technical replicate, mean ± SD). ****= P ≤ 0.001 by 2-way ANOVA with Šídák’s multiple comparisons test. ( F ) Various cell lines were analyzed for LIF expression by ELISA. Data are presented as mean ± SD ( n = 3. Technical replicates). ( G ) GFP-expressing DFCI112F and DFCI190F cells were incubated with CM from their corresponding adherent cell line pairs pretreated with either LIF neutralizing antibody (500 ng/mL) or control IgG and monitored in real time via IncuCyte imager for green fluorescence intensity. ( H and I ) GFP expressing DFCI112F ( H ) and DFCI190 ( I ) cells were incubated with CM from their adherent cell line pairs pretreated with siRNA against LIF or unrelated sequence and monitored via IncuCyte imager. LIF knockdown efficiency was tested using ELISA ( n = 3, technical replicate, mean ± SD). ( J ) The schema illustrating the interaction between NE and non-NE tSCLC cells through LIF.

    Journal: JCI Insight

    Article Title: EGFR -mutant transformed small cell lung cancer harbors intratumoral heterogeneity targetable with MEK inhibitor combination therapy

    doi: 10.1172/jci.insight.197008

    Figure Lengend Snippet: ( A ) Heatmap of cell viability after 5 days’ treatment with 1 μmol/L of each single agent (rows) per various lung cancer cell lines (columns) relative to DMSO control. Commercially available agents used are in . ( B ) Bar graph of IC 50 values of various indicated lung cancer cell lines in response to trametinib. IC 50 of NE and non-NE tSCLC cell lines is shown in red and blue, respectively. ( C ) Dose-response curve of trametinib in tSCLC cell lines (blue: NE, red: non-NE). Cell viability was assessed by CTG after 120 hours ( n = 6, technical replicate, mean ± SD). ( D ) NE tSCLC cell viability was assayed by CTG following treatment with indicated concentration of LIF and IL-6 for 5 days. ( E ) qPCR analysis of LIF mRNA expression levels in non-NE tSCLC cell lines treated with 10 nmol/L trametinib 2 and 6 hours. Gene expression was normalized to GUSB and shown as relative to that of DMSO-treated control ( n = 3, technical replicate, mean ± SD). ****= P ≤ 0.001 by 2-way ANOVA with Šídák’s multiple comparisons test. ( F ) Various cell lines were analyzed for LIF expression by ELISA. Data are presented as mean ± SD ( n = 3. Technical replicates). ( G ) GFP-expressing DFCI112F and DFCI190F cells were incubated with CM from their corresponding adherent cell line pairs pretreated with either LIF neutralizing antibody (500 ng/mL) or control IgG and monitored in real time via IncuCyte imager for green fluorescence intensity. ( H and I ) GFP expressing DFCI112F ( H ) and DFCI190 ( I ) cells were incubated with CM from their adherent cell line pairs pretreated with siRNA against LIF or unrelated sequence and monitored via IncuCyte imager. LIF knockdown efficiency was tested using ELISA ( n = 3, technical replicate, mean ± SD). ( J ) The schema illustrating the interaction between NE and non-NE tSCLC cells through LIF.

    Article Snippet: LIF neutralizing antibody (AF-250-NA), IL-6 neutralizing antibody (AF-206-NA), and control antibody (AB-108-C) were purchased from R&D Systems.

    Techniques: Control, Concentration Assay, Expressing, Gene Expression, Enzyme-linked Immunosorbent Assay, Incubation, Fluorescence, Sequencing, Knockdown